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SIGNIFICANCE OF HAPLOTYPE B DONORS AND GENE CONTENT MOTIFS
IN NONMYELOABLATIVE, HLA-HAPLOIDENTICAL (Haplo) BMT WITH
POSTTRANSPLANTATION HIGH-DOSE CYCLOPHOSPHAMIDE (PT/Cy)
Symons, H.J., Munchel, A.T., Rossiter, N.L., Kasamon, Y.L., Jones, R.J.,
Fuchs, E.J., Leffell, M.S. Johns Hopkins University, Baltimore, MD
Killer immunoglobulin receptors (KIRs) regulate natural killer
cell function, and can influence BMT outcome. We studied the re-
lationship of KIR haplotype and gene content motifs in 208 patients
who received nonmyeloablative haploBMTand PT/Cywith the goal
of identifying a clinically applicable donor selection strategy that
could improve the success of this transplant platform. The prepara-
tive regimen consisted of fludarabine (30mg/m2 IV days -6 to -2), Cy
(14.5 mg/kg IV days -6 and -5), total body irradiation (200 cGy day
-1), and T-cell replete bone marrow infusion. GVHD prophylaxis
consisted of PT/Cy (50 mg/kg IV days 3 and 4), mycophenolate mo-
fetil days 5-35, and tacrolimus days 5-180. All patients (median age
52, range 1-73) had poor-risk hematologic malignancies (65% lym-
phoid and 35% myeloid). 75% of recipients had Haplotype B do-
nors. Median follow-up was 2.7years (range, 0.5-5years), for those
without events.We confirmed that recipients with haplotype B/x do-
nors had an improved overall survival (OS) (median 1081 vs. 608
days, p 5 0.06) and progression free survival (PFS) over those with
A/A donors (median 363 days vs. 170 days, p 5 0.06) (Table 1), as
previously reported. Interestingly, a protective effect of donor B/x
was observed on OS and PFS for those with lymphoid malignancies
(p5 0.01 and p5 0.03, Table 1), but not for those with myeloid ma-
lignancies. In order to identify which particular donor B-specific
genes improved outcome, centromeric (Cen) and telomeric (Tel)
parts of the KIR locus were assigned according to the presence or ab-
sence of one or more B haplotype-defining KIR genes. We found
a significant benefit on OS and PFS from donors with a Cen A/B ge-
notype as compared with Cen A/A (p 5 0.03, p 5 0.03) as well as
some benefit from the Tel B/B genotype as compared with Tel A/
A (p 5 0.06, p 5 0.09). Donors with KIR B-content scores of $2
had a tendency towards an improved OS (p 5 0.1) and PFS (p 5
0.06) (Table 1). We found no effect of KIR haplotype on relapse
or acute GVHD, however there was a tendency towards an improved
non-relapse mortality in lymphoid recipients with haplotype B do-
nors (p 5 0.1) and in all recipients with Cen A/B donors (p 5
0.12). We did not see a significant benefit of inhibitory KIR gene
mismatches on outcome. Selection of haplotype B donors, particu-
larly for A/A recipients with lymphoid malignancies, may be war-
ranted after haploBMT with PT/Cy. Further selection of donors
with Cen A/B and/or Tel B/B genotypes may also be useful.
Table 1. Effect of KIR Haplotype and Gene Content Motifs on
OS and PFS
Median OS Median PFSN OS (days) p-value PFS (days) p-valueDonor HaplotypeEntire CohortB/x 153 1081 0.06 363 0.06A/A 55 608 170LymphoidB/x 36 887 0.01 432 0.03A/A 97 215 153Donor B ContentEntire Cohort>/ 5 2 58 1308 0.1 474 0.06< 2 150 681 202Lymphoid>/ 5 2 38 1308 0.07 469 0.15< 2 95 441 201Donor Cen GenotypeEntire CohortA/B 95 1308 A/B vs A/A 0.03 432 A/B vs A/A 0.03B/B 24 586 A/B vs B/B 0.19 333 A/B vs B/B 0.70A/A 89 580 B/B vs A/A 0.87 198 B/B vs A/A 0.32LymphoidA/B 62 1308 A/B vs A/A 0.03 441 A/B vs A/A 0.19B/B 14 477 A/B vs B/B 0.14 218 A/B vs B/B 0.34(Continued )Table. (Continued)NMedian
OS (days)OS
p-valueMedian
PFS (days)PFS
p-valueA/A 57 268 A/A vs B/B 0.97 201 A/A vs B/B 0.10Donor Tel GenotypeEntire CohortB/B 24 undefined B/B vs A/A 0.06 1147 B/B vs A/A 0.09A/B 65 814 B/B vs A/B 0.09 246 B/B vs A/B 0.14A/A 130 681 A/A vs A/B 0.59 213 A/B vs A/A 0.79LymphoidB/B 9 undefined B/B vs A/A 0.06 1365 B/B vs A/A 0.08A/B 42 887 B/B vs A/B 0.09 388 B/B vs A/B 0.20A/A 82 441 A/A vs A/B 0.25 178.5 A/A vs A/B 0.23OS5Overall survival; PFS5 Progression Free Survival; Cen5Centro-
meric; Tel 5 Telomeric.42
BENEFICIAL EFFECT OF HIGH-DOSE IV BUSULFAN (BU) DELIVERED BY
PROLONGED CONTINUOUS INFUSION (CI) ON RELAPSE RATE AND
OVERALL SURVIVAL (OS) IN MATCHED RELATED AND UNRELATED AL-
LOGENEIC TRANSPLANT PATIENTS WITH HEMATOLOGIC MALIGNAN-
CIES
Walko, C.1, Ivanova, A.2,Whitley, J.1, Rao, K.3, Gabriel, D.1, Serody, J.1,
Comeau, T.1, Coghill, J.1, Armistead, P.1, Sarantopoulos, S.1, Wood, W.1,
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Introduction:Dose escalation of chemotherapy and radiation in al-
logeneic transplant conditioning regimens has lowered relapse rates
but not usually improved overall survival because of higher treatment
relatedmortality. The availability of IV BUhas allowedmore precise
dosing and dose escalation of this drug.
Methods:Test dose (.8 mg/kg) BUwas administered one week prior
to start of the conditioning regimen and the desired AUC calculated
from the clearance. Dose levels were escalated in 20% increments
from 4800 to 5760, 6912, 7603 and 8663 uM-min/24 hours from
day -7 to -3 over 90 hours with fludarabine, 30 mg/m2/d on days
-7 to -3. All pts received tacrolimus and either alemtuzamab alone,
or low dose methotrexate (mtx) +/- ATG for GVH prophylaxis.
Results: 55 high risk pts, age 39 (22-54), 20 MRD, 35 MUD, 29
AML, 7 ALL, 8 MDS, 5 NHL, 6 other, were enrolled on this IRB
approved study. 30 pts received alemtuzamab, 19 ATG + mtx and
6 mtx only. Mean achieved AUCs by dose level were 4973 (14 pts),
5638 (7 pts), 7131 (25 pts), 7053 (7 pts), and 8680 (2 pts) uM-min/
24 hrs. The MTD was level 3. Grade 4 DLTs were mucositis in
2/2 at level 5 and 1/7 at level 4 and reversible VOD in 1/7 at level
4. Three additional grade 5 treatment-related toxicities were seen
at dose level 1 (liver failure), level 2 (mucositis) and level 3 (VOD).
The total incidence of grade 4 or 5 VOD was 2/55 or 4%.When di-
vided by AUC into three groups of 19, 19, and 17 pts each, median
AUC values were 5106, 6431, and 7693 uMol-min/24 hrs, respec-
tively.MedianOS in days were 298, 353, andNot Reached and times
to relapse were 191, 353, and 818, for the lowest, middle and highest
AUC groups, respectively. Two-year OS and RFS for the lowest,
middle and highest groups were .24, .41, and .70 and .20, .35, and
.63, respectively. Differences in relapse and OS were significant at
the .053 and .063 levels, respectively. Relapse related death was
much higher in the lowest AUC group (9/19 vs 1/17, p 5 .013),
but there was no difference in non-relapse deaths between the
groups; 6/19, 7/19, and 4/17, p 5 .663. In multivariable analysis,
higher AUC dose, use of ATG rather than alemtuzamab and having
aMUDdemonstrated a trend toward improved outcomes with AUC
being the strongest predictor.
Conclusion: High AUC levels of busulfan can be safely achieved
with CI leading to improved overall survival and decreased relapse
rates in patients undergoing matched related or unrelated allogeneic
transplantation.
